Medtronic Plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $37.5B+11.9% YoYTTM through 31 Jul 2026
Net Income $5.2B+12.2% YoYTTM through 31 Jul 2026
Free Cash Flow $6.1BTTM through 31 Jul 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 25.9% |
| Operating Margin | 18.1% |
| Net Margin | 13.9% |
Returns
10.4%ROE
5.6%ROA
6.8%ROIC
Balance Sheet Health
Debt / Equity0.56x
Current Ratio2.07x
Net Debt$26.4B
Cash & Equivalents$1.7B
Quality Metrics
Altman Z-Score2.94
Piotroski F-Score6 / 9
FCF Margin16.3%
Rule of 4019.8
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2026: $36.4B
Diluted EPS$4.06TTMFY2026: $3.73
Dividend
$2.14Per share, FY20262.36%Yield-2.4%5-yr growth
Capital Allocation
Capex Intensity5.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cardiovascular Portfolio | $14B | ||
| Neuroscience Portfolio | $10.3B | +4.5% | |
| Medical Surgical Portfolio | $8.9B | +4.9% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.